Regeneron Pharmaceuticals Inc. buy Truist Financial Co.
Summary
This prediction is currently active. With a performance of 47.39% the BUY prediction by Truist_Financial_Co_ is a big success. This prediction currently runs until 28.11.24. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | -0.509% | -0.509% |
iShares Core DAX® | 1.056% | 1.056% |
iShares Nasdaq 100 | -1.886% | -0.160% |
iShares Nikkei 225® | 2.553% | 4.359% |
iShares S&P 500 | -0.434% | 0.224% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Truist_Financial_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
26.08.24
Regeneron Pharmaceuticals Inc.
03.04.24
03.04.25
26.08.24
Regeneron Pharmaceuticals Inc.
26.03.24
26.03.25
26.08.24
Regeneron Pharmaceuticals Inc.
18.12.23
18.12.24
26.08.24
Regeneron Pharmaceuticals Inc.
16.08.23
16.08.24
17.08.24